Katja Cvan Trobec1, Iztok Grabnar1, Mojca Kerec Kos1, Tomaz Vovk1, Jurij Trontelj1, Stefan D Anker2, Giuseppe Rosano3,4, Mitja Lainscak5,6. 1. Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia. 2. Innovative Clinical Trials, Department of Cardiology and Pneumology, University Medical Center Göttingen (UMG), Göttingen, Germany. 3. Centre for Clinical and Basic Research, Department of Medical Sciences, IRCCS San Raffaele Pisana, Rome, Italy. 4. Cardiovascular and Cell Science Research, St George's University, London, UK. 5. Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia. mitja.lainscak@guest.arnes.si. 6. Department of Cardiology, General Hospital Celje, SI-3000, Celje, Slovenia. mitja.lainscak@guest.arnes.si.
Abstract
PURPOSE: We investigated bisoprolol pharmacokinetics, including longitudinal changes and importance of patient characteristics in chronic heart failure. METHODS: Forty-six patients with chronic heart failure (57 % male, NYHA class I/II/III = 2/36/8) were followed for an average of 8 ± 2 months. At baseline and follow-up, plasma bisoprolol concentrations were determined and body composition was measured using dual-energy X-ray absorptiometry. A bisoprolol pharmacokinetic model was built with non-linear mixed-effects modeling to analyze the association with various parameters of body composition. RESULTS: Mean bisoprolol clearance (10.2 L/h) was 30 % lower than in healthy individuals and correlated with MDRD4-estimated renal function. The mean volume of distribution (230 L) was similar to healthy population and was associated with total body mass and skeletal muscle index (SMI). During follow-up, we observed minor changes in the absorption rate constant (2.83 vs. 2.27 h(-1), P = 0.030) and volume of distribution (227 vs. 250 L, P = 0.004), which are not clinically relevant. CONCLUSIONS: In patients with chronic heart failure, bisoprolol clearance was associated with estimated renal function; thus, in moderately and severely decreased renal function, patients may need to have their dose adjusted. Patients with low body weight or low SMI have greater fluctuations and higher maximal plasma concentrations of bisoprolol because of the lower volume of distribution. Longitudinal changes of bisoprolol pharmacokinetics were not associated with changes in body composition.
PURPOSE: We investigated bisoprolol pharmacokinetics, including longitudinal changes and importance of patient characteristics in chronic heart failure. METHODS: Forty-six patients with chronic heart failure (57 % male, NYHA class I/II/III = 2/36/8) were followed for an average of 8 ± 2 months. At baseline and follow-up, plasma bisoprolol concentrations were determined and body composition was measured using dual-energy X-ray absorptiometry. A bisoprolol pharmacokinetic model was built with non-linear mixed-effects modeling to analyze the association with various parameters of body composition. RESULTS: Mean bisoprolol clearance (10.2 L/h) was 30 % lower than in healthy individuals and correlated with MDRD4-estimated renal function. The mean volume of distribution (230 L) was similar to healthy population and was associated with total body mass and skeletal muscle index (SMI). During follow-up, we observed minor changes in the absorption rate constant (2.83 vs. 2.27 h(-1), P = 0.030) and volume of distribution (227 vs. 250 L, P = 0.004), which are not clinically relevant. CONCLUSIONS: In patients with chronic heart failure, bisoprolol clearance was associated with estimated renal function; thus, in moderately and severely decreased renal function, patients may need to have their dose adjusted. Patients with low body weight or low SMI have greater fluctuations and higher maximal plasma concentrations of bisoprolol because of the lower volume of distribution. Longitudinal changes of bisoprolol pharmacokinetics were not associated with changes in body composition.
Entities:
Keywords:
Bisoprolol; Body composition; Cachexia; Chronic heart failure; Pharmacokinetics
Authors: Ian Janssen; Richard N Baumgartner; Robert Ross; Irwin H Rosenberg; Ronenn Roubenoff Journal: Am J Epidemiol Date: 2004-02-15 Impact factor: 4.897
Authors: Vanessa Fontana; Richard Myles Turner; Ben Francis; Peng Yin; Benno Pütz; Timo P Hiltunen; Sanni Ruotsalainen; Kimmo K Kontula; Bertam Müller-Myhsok; Munir Pirmohamed Journal: Pharmgenomics Pers Med Date: 2022-03-22
Authors: Josée Bouchard; Greene Shepherd; Robert S Hoffman; Sophie Gosselin; Darren M Roberts; Yi Li; Thomas D Nolin; Valéry Lavergne; Marc Ghannoum Journal: Crit Care Date: 2021-06-10 Impact factor: 9.097
Authors: Laura Molenaar-Kuijsten; Bart Albertus Wilhelmus Jacobs; Sophie Alberdine Kurk; Anne Maria May; Thomas Petrus Catharina Dorlo; Jacob Hendrik Beijnen; Neeltje Steeghs; Alwin Dagmar Redmar Huitema Journal: Cancer Med Date: 2021-06-14 Impact factor: 4.452